PURPOSE: The addition of platinum-based chemotherapy (ChRT) or cetuximab (ExRT) to
concurrent radiotherapy (RT) has resulted in improved survival in Phase III studies for
locoregionally advanced head and neck cancer (LAHNC). However the optimal treatment
regimen has not been defined. A retrospective study was performed to compare outcomes in
patients who were treated definitively with ExRT or ChRT. METHODS: Cetuximab with
concurrent RT was used to treat 29 patients with LAHNC, all of whom had tumors of the oral …